Why the study?
Single-pill combination therapies may improve blood pressure control, motivating an evaluation of the real-life use and effect of first-line versus replacement irbesartan/hydrochlorothiazide combinations.
Does single-pill combination therapy with irbesartan and hydrochlorothiazide improve systolic blood pressure control in patients with moderate or severe hypertension?
Population
780 patients with moderate or severe hypertension either untreated or uncontrolled
Comparison
First-line vs replacement single-pill combination therapy with irbesartan and HCTZ
Design
Prospective nationwide cohort study
Follow-up
8-week follow-up
Authors
Loading...
Single-pill irbesartan/HCTZ was associated with substantial SBP reductions and 47% goal attainment in real-world stage II/III hypertension; leaves open superiority over sequential monotherapy.
Does single-pill combination therapy with irbesartan and hydrochlorothiazide improve systolic blood pressure control in patients with moderate or severe hypertension?
Single-pill combination of irbesartan and hydrochlorothiazide effectively reduces blood pressure in moderate to severe hypertension, with better control rates when used as first-line therapy.
Spirk et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: